Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE
· Real-Time Price · USD
6.68
0.02 (0.30%)
At close: Sep 26, 2025, 11:05 AM
0.30% (1D)
| Bid | 6.68 |
| Market Cap | 1.06B |
| Revenue (ttm) | 93.95M |
| Net Income (ttm) | -129.87M |
| EPS (ttm) | -0.8 |
| PE Ratio (ttm) | -8.35 |
| Forward PE | -5.7 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 6.69 |
| Volume | 327,092 |
| Avg. Volume (20D) | 1,883,123 |
| Open | 6.70 |
| Previous Close | 6.66 |
| Day's Range | 6.58 - 6.74 |
| 52-Week Range | 5.28 - 16.74 |
| Beta | -1.16 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for WVE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsWave Life Sciences Ltd. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-16.84%
Wave Life Sciences shares are trading lower. The c...
Unlock content with
Pro Subscription
1 month ago
+1.39%
Wave Life Sciences shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a price target of $19.
3 weeks ago · https://thefly.com
Wave Life Sciences price target lowered to $18 from $21 at Wells FargoWells Fargo analyst Tiago Fauth lowered the firm's price target on Wave Life Sciences to $18 from $21 and keeps an Overweight rating on the shares after the company reported AATD data update for 200 a...
1 month ago · fool.com
Wave (WVE) Q2 Revenue Drops 56%Wave (WVE) Q2 Revenue Drops 56%
2 months ago · seekingalpha.com
Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 MonthsWave Life Sciences Ltd. is an innovative biotech with soli data for its AATD, Huntington's, and DMD programs. Its share price is nevertheless down 44% year-to-date, potentially creating a buying oppor...